Half-Life (Normalesrd) Hours
1/13-23
Plasma Protein Binding %
41-75
Volume Of Distribution L/Kg
0.2
Dose For Normal Renal Function
1-2 g q6-8h
Adjustment For Renal Failure Method
I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
q6-8h [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
q8-12h [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
q24-48h [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: 1 g after dialysis
Supplement For Dialysis [Recommendation Level]: Pd
PD: 1 g/d
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [B]
References
Arvidsson A, Alvá n G, Tranaeus A, Malmborg AS. Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol. 1985; 28: 333-7. [PMID: 4007038] / Brogden RN, Heel RC, Speight TM, Avery GS. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979; 17: 1-37. [PMID: 369806] / Fillastre JP, Leroy A, Godin M, Oksenhendler G, Humbert G. Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients. J Antimicrob Chemother. 1978; 4: 79-83. [PMID: 690027] / Garcia MJ, Dominguez-Gil A, Tabernero JM, Diaz Molina M. Pharmacokinetics of cefoxitin during haemofiltration. Eur J Clin Pharmacol. 1983; 25: 395-8. [PMID: 6628529] / Golper TA. Drug removal during continuous hemofiltration or hemodialysis. Contrib Nephrol. 1991; 93: 110-6. [PMID: 1802557] / Golper TA, Marx MA. Drug dosing adjustments during continuous renal replacement therapies. Kidney Int Suppl. 1998; 66: S165-8. [PMID: 9573596]